MYSZ

Business Context and Reporting Period

Company: Topspin Medical, Inc. (Note: Input metadata referenced "My Size, Inc.", but the filing text identifies the registrant as Topspin Medical, Inc.)
Reporting Period: Quarter ended September 30, 2010 (Unaudited)
Status: Development Stage Company; Debtor-in-Possession under Chapter 11 bankruptcy proceedings filed in July 2010.
Operations: Operational activities were suspended in October 2008. The company ceased R&D in January 2010. Current activities are limited to administrative functions and bankruptcy restructuring.

Key Financial Metrics

Note: Financial statements are presented in New Israeli Shekels (NIS). Approximate USD conversions provided in text: Cash ~$16,000; Net Loss (9mo) ~$500,000; Accumulated Deficit ~$50.2M.

Material Changes vs. Prior Period

• Liquidity Crisis: Cash and cash equivalents plummeted from NIS 1,002,000 (Dec 31, 2009) to NIS 58,000 (Sep 30, 2010), a decrease of approximately 94%.
• Debt Structure: A new loan of approximately NIS 1,102,000 (approx. $300,000) from a related party (Medgenesis Partners Ltd.) was recorded in current liabilities, replacing a previously cancelled investment agreement.
• Expense Reduction: General and Administrative expenses for the nine months ended Sep 30, 2010 (NIS 1,997,000) decreased compared to the same period in 2009 (NIS 2,061,000), reflecting the suspension of operations and reduced headcount.
• Bankruptcy Filing: The company filed for Chapter 11 protection in July 2010, a material change in legal status not present in the prior year.

Outlook, Risks, and Management Commentary

• Going Concern: Management states there is substantial doubt about the company's ability to continue as a going concern. The company has not generated revenue since inception and relies entirely on financing.
• Restructuring Plan: The company is pursuing a Chapter 11 settlement involving a 1:500 reverse stock split and the conversion of Medgenesis loans into equity. As of the filing date, the Bankruptcy Court had approved the disclosure statement, with a confirmation hearing scheduled for December 20, 2010.
• Capital Needs: The company requires additional funds to redeem long-term liabilities and continue operations. The current loan from Medgenesis is intended to cover expenses for the next 12 months, but future capital raising is uncertain.
• Internal Controls: The company identified a material weakness in internal controls over financial reporting due to a lack of resources in the finance department, resulting in inadequate allocation of responsibilities.
• Regulatory Status: The Tel Aviv Stock Exchange (TASE) removed the company's shares to the "preservation list" in July 2010 due to equity falling below NIS 2,000.

Investor Verification Checklist

• Bankruptcy Confirmation: Verify if the Chapter 11 plan was confirmed by the Delaware Bankruptcy Court on or after December 20, 2010.
• Capitalization Post-Plan: Confirm the final share count and ownership structure following the proposed 1:500 reverse split and debt-to-equity conversion.
• Related Party Control: Assess the extent of control held by Medgenesis Partners Ltd. (projected to hold ~87% of equity post-settlement) and the terms of the remaining debt.
• Cash Runway: Verify current cash balances and whether the company has secured the additional funding required to meet ongoing obligations beyond the initial loan.
• Delisting Risk: Monitor the status of the company's listing on the Tel Aviv Stock Exchange and potential delisting from U.S. markets.